Continue Jardiance (Dapagliflozin) in This Patient
In a patient with well-controlled type 2 diabetes (A1C 5.5%) on dapagliflozin who also has heart failure, dapagliflozin should absolutely be continued—and the indication has now shifted from diabetes management to heart failure treatment. The cardiovascular and heart failure benefits of SGLT2 inhibitors like dapagliflozin are independent of their glucose-lowering effects and persist regardless of baseline A1C levels 1.
Why Continuation is Critical
Heart Failure Takes Priority Over Glycemic Control
The FDA-approved indication for Jardiance (empagliflozin, same class as dapagliflozin) explicitly includes reducing cardiovascular death and hospitalization for heart failure in adults with heart failure, independent of diabetes status 2. Multiple guidelines now position SGLT2 inhibitors as foundational therapy for heart failure across the entire ejection fraction spectrum 1, 3, 1.
The 2024 ADA Standards of Care state clearly: In patients with type 2 diabetes and established heart failure (either HFpEF or HFrEF), an SGLT2 inhibitor with proven benefit is recommended to reduce worsening heart failure and cardiovascular death, and to improve symptoms, physical limitations, and quality of life 1. These benefits appear unrelated to glucose lowering, given comparable outcomes in people with and without diabetes 1.
Evidence Supporting Continuation Regardless of A1C
The landmark DAPA-HF trial demonstrated that dapagliflozin reduced cardiovascular death or worsening heart failure by 26% (HR 0.74) in patients with heart failure and reduced ejection fraction, with consistent benefits regardless of diabetes status or baseline A1C level 1, 4. Critically, 55% of DAPA-HF participants did not have diabetes at baseline, and the effect was similar at any hemoglobin A1c level 5.
In a specific analysis examining patients without diabetes stratified by A1C <5.7% vs ≥5.7%, dapagliflozin reduced the primary outcome in both groups with no interaction (HR 0.67 and 0.74, respectively; p for interaction = 0.72) 4. Even in patients with A1C <5.7%—lower than your patient's 5.5%—dapagliflozin provided significant cardiovascular benefit 4.
The DELIVER trial extended these findings to heart failure with preserved ejection fraction (EF >40%), showing an 18% reduction in worsening heart failure or cardiovascular death, again with consistent results regardless of diabetes presence 1, 3, 1.
The Mechanism is Not Glucose-Dependent
The cardiovascular benefits of SGLT2 inhibitors operate through mechanisms independent of glycemic control: anti-inflammatory and antifibrotic effects, reduced oxidative stress, improved endothelial function, and favorable cardiac remodeling 3. This explains why benefits are seen equally in patients with and without diabetes, and across all A1C ranges 1, 5.
Research specifically examining decompensated heart failure patients with diabetes found that SGLT2 inhibitors improved heart failure outcomes (decreased BNP levels) irrespective of HbA1c level, even though urine glucose excretion and volume effects differed by glycemic control 6.
Practical Implementation
Dosing Remains Standard
- Dapagliflozin 10 mg once daily is the evidence-based dose for heart failure, regardless of diabetes status or A1C level 1, 3, 7
- This is the same dose used in DAPA-HF and DELIVER trials 1
Monitoring Considerations
While the A1C is well-controlled at 5.5%, monitor for:
- Hypoglycemia risk is minimal with dapagliflozin monotherapy, but if the patient is on insulin or sulfonylureas for diabetes, those agents may need dose reduction 5, 2
- Volume status: Assess for signs of volume depletion, though this was not excessive in trials 1, 8
- Renal function: DAPA-HF excluded patients with eGFR <30 mL/min/1.73 m², though dapagliflozin slowed eGFR decline in both diabetic and non-diabetic cohorts 5
- Genital mycotic infections: Most common adverse effect (10-15% in women), typically manageable without discontinuation 5, 2
Common Pitfall to Avoid
Do not discontinue dapagliflozin simply because diabetes is "well-controlled." This represents a fundamental misunderstanding of SGLT2 inhibitor pharmacology in heart failure. The 2021 CCS/CHFS guidelines explicitly state that SGLT2 inhibitors should be used in patients with HFrEF with or without concomitant type 2 diabetes 5.
Post-hoc analyses show that treatment benefits may decline rapidly after SGLT2 inhibitor discontinuation, making persistence of treatment critical 9.
Reframing the Indication
Consider documenting that dapagliflozin is being continued primarily for heart failure management rather than diabetes control. This clarifies the therapeutic rationale and may help with insurance coverage, as the FDA indication for heart failure does not require diabetes 2.
Supporting Guideline Consensus
The 2022 ACC/AHA/HFSA Heart Failure Guidelines give a Class 1 (Strong) recommendation for SGLT2 inhibitors in symptomatic chronic HFrEF to reduce hospitalizations and cardiovascular mortality 8. The 2021 CCS/CHFS guidelines similarly provide a Strong Recommendation with High-Quality Evidence for SGLT2 inhibitor use in HFrEF patients with or without diabetes 5.
The 2025 Canadian Cardiovascular Society guideline update reinforces that SGLT2 inhibitors should be integrated into management plans for patients with heart failure across the ejection fraction spectrum 3.
Bottom line: Your patient's excellent glycemic control (A1C 5.5%) does not diminish—and may actually highlight—the importance of continuing dapagliflozin for its proven heart failure benefits, which are entirely independent of glucose lowering.